LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

West Pharmaceutical Services Inc

Chiusa

SettoreSettore sanitario

267.92 -0.51

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

266.04

Massimo

270.3

Metriche Chiave

By Trading Economics

Entrata

8.2M

140M

Vendite

38M

804M

P/E

Media del settore

40.335

76.798

EPS

1.96

Rendimento da dividendi

0.31

Margine di Profitto

17.406

Dipendenti

10,600

EBITDA

19M

217M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+30.87% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.31%

2.37%

Prossima data del Dividendo

4 feb 2026

Prossima data del' Ex Dividendo

28 gen 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-209M

20B

Apertura precedente

268.43

Chiusura precedente

267.92

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

West Pharmaceutical Services Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 dic 2025, 23:54 UTC

Azioni calde

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 dic 2025, 23:51 UTC

Utili

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 dic 2025, 23:39 UTC

I principali Market Mover

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 dic 2025, 21:40 UTC

Utili

Nike Sales Tick Up, But China Weakness Persists

18 dic 2025, 23:56 UTC

I principali Market Mover

WiseTech Rises After Board Clears Executive Chair of Allegations

18 dic 2025, 23:45 UTC

Discorsi di Mercato

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 dic 2025, 23:37 UTC

Discorsi di Mercato
Utili

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 dic 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 dic 2025, 23:03 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 dic 2025, 23:02 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 dic 2025, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 dic 2025, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 dic 2025, 22:58 UTC

Acquisizioni, Fusioni, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 dic 2025, 22:57 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 dic 2025, 22:56 UTC

Acquisizioni, Fusioni, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 dic 2025, 22:55 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:59 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

18 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 dic 2025, 21:35 UTC

Utili

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 dic 2025, 21:31 UTC

Utili

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Greater China Rev Down 17% >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q EPS 53c >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Apparel Rev $3.91B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Equipment Rev $550M >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q N Amer Rev $5.63B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Footwear Rev $7.66B >NKE

18 dic 2025, 21:15 UTC

Utili

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

Confronto tra pari

Modifica del prezzo

West Pharmaceutical Services Inc Previsione

Obiettivo di Prezzo

By TipRanks

30.87% in crescita

Previsioni per 12 mesi

Media 348.7 USD  30.87%

Alto 375 USD

Basso 285 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per West Pharmaceutical Services Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

10

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

213.26 / 219.27Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
help-icon Live chat